MELTZER LESLIE has filed 11 insider transactions across 1 company since August 2025.
Most recent transaction: a disposition of 92592 shares of Apellis Pharmaceuticals, Inc. ($APLS) on May 14, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | D | Stock Option (right to buy) | 92592 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.07% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | D | Common Stock | 45220 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.03% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | D | Common Stock | 61804 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.05% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | D | Common Stock | 45220 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.03% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | U | Common Stock | 107024 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.08% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | A | Common Stock | 22610 | $0.00 | 22,610.0000 | 130,067,000 | 9999.99% | 0.02% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | D | Common Stock | 22610 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.02% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | A | Common Stock | 45220 | $0.00 | 45,220.0000 | 130,067,000 | 9999.99% | 0.03% |
| Jan. 28, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | A | Common Stock | 45220 | $0.00 | 107,024.0000 | 130,067,000 | 73.17% | 0.03% |
| Aug. 26, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | A | Stock Option (Right to Buy) | 92592 | $0.00 | 92,592.0000 | 123,905,000 | 9999.99% | 0.07% |
| Aug. 26, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | A | Common Stock | 61804 | $0.00 | 61,804.0000 | 123,905,000 | 9999.99% | 0.05% |